NP

• XTM Inc. ("XTM" or the "Corporation") (QB: XTMIF / CSE: PAID / FSE: 7XT) is providing an update to its previously announced management cease trade order (the "MCTO") granted by the Ontario Securities Commission (the “OSC”) under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").
• The delay in filing the required documents is in connection with to a recent change of auditor for the Corporation and audit requirements resulting from increased transaction volume experienced by the Corporation.
• The MCTO does not affect the ability of other shareholders to trade their securities.
• In addition to the late filing of the Required Documents, the Company does not believe it will be in a position to file its interim financial statements, management’s discussion and analysis and related certifications for the three-month financial period ended March 31, 2023 (the “Additional Disclosure Documents”).

• ADHD is diagnosed using criteria from a document called DSM-5, which include symptoms of inattention, hyperactivity and impulsivity.
• But it is becoming increasingly clear to researchers that the condition also comes with self-control problems, affecting the ability to regulate emotions.
• For example, 2.1% of children with a diagnosis of ADHD also have a mood disorder, such as depression, while 27.4% have an anxiety disorder.
• Children with anxiety and depression symptoms only exhibited those deficits if they also had problems with attention.
• So it seems that one possible route to helping children with ADHD or mood disorders with cognitive development is to focus on improving their attention.

Treatments

• Methylphenidate roughly works by increasing three chemicals in the brain: dopamine, serotonin and noradrenaline.
• Dopamine can improve attention, learning, working memory and motivation, while noradrenaline reduces impulsivity and boosts attention.
• This research suggests that cognitive control, which is associated with frontal areas, can be improved by methylphenidate.
• This should be offered to children with ADHD, in conjunction with pharmacological treatments.

ADHD on the rise

• The number of ADHD diagnoses are rising across the world, and so are prescriptions of methylphenidate.
• In the UK, a study estimated that the use of ADHD medications has increased by almost 800% from 2000 to 2015.
• It may be that the prevalence of ADHD will increase even more in the future as coping strategies become less effective and people seek help and ultimately receive a diagnosis.
• The more we learn about brain basis of ADHD, the easier it will get to treat.

• Azafaros B.V. today announced that the first patient has been enrolled into its Phase 2 RAINBOW study ( NCT05758922 ).
• Azafaros is developing the compound as a potentially disease-modifying treatment in severe metabolic disorders including GM1 and GM2 gangliosidoses and NP-C. Enrollment of the first patient in the study is an important milestone for Azafaros in its mission to bring new treatment options to these patients and their families.
• The Phase 2 RAINBOW study is a randomized, double-blind, placebo-controlled, multicenter, 12-week trial assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZ-3102 in patients with GM2 gangliosidosis and NP-C.
• Patients who complete the 12-week study period will be offered a double-blind extension if approved by the country’s health authorities.

• The Company is diligently working with its auditors to conclude the filings at the earliest possible time.
• The Company announced via press release dated April 3, 2023 (the “Delayed Filing Announcement”) that it had submitted an application to the BCSC for a management cease trade order (the “MCTO”) pursuant to NP 12-203.
• The MCTO was issued by the BCSC on April 3, 2023 extending the deadline for filing the Annual Filings to May 30, 2023.
• The revocation of the FTFCTO is expected to occur within a few days after the Required Documents are filed.